Sartorius Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Joachim Kreuzburg

Algemeen directeur

€1.8m

Totale compensatie

Percentage CEO-salaris	59.5%
Dienstverband CEO	22yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	7.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Joachim Kreuzburg's beloning veranderd ten opzichte van Sartorius's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	€77m
Jun 30 2024	n/a	n/a	€78m
Mar 31 2024	n/a	n/a	€149m
Dec 31 2023	€2m	€1m	€205m
Sep 30 2023	n/a	n/a	€358m
Jun 30 2023	n/a	n/a	€495m
Mar 31 2023	n/a	n/a	€566m
Dec 31 2022	€2m	€1m	€678m
Sep 30 2022	n/a	n/a	€534m
Jun 30 2022	n/a	n/a	€489m
Mar 31 2022	n/a	n/a	€434m
Dec 31 2021	€3m	€1m	€319m
Sep 30 2021	n/a	n/a	€372m
Jun 30 2021	n/a	n/a	€332m
Mar 31 2021	n/a	n/a	€254m
Dec 31 2020	€2m	€903k	€210m
Sep 30 2020	n/a	n/a	€181m
Jun 30 2020	n/a	n/a	€154m
Mar 31 2020	n/a	n/a	€165m
Dec 31 2019	€2m	€888k	€157m
Sep 30 2019	n/a	n/a	€171m
Jun 30 2019	n/a	n/a	€166m
Mar 31 2019	n/a	n/a	€153m
Dec 31 2018	€2m	€863k	€141m
Sep 30 2018	n/a	n/a	€138m
Jun 30 2018	n/a	n/a	€126m
Mar 31 2018	n/a	n/a	€115m
Dec 31 2017	€2m	€832k	€115m

Compensatie versus markt: De totale vergoeding ($USD 1.88M ) Joachim } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.85M ).

Compensatie versus inkomsten: De vergoeding van Joachim is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Joachim Kreuzburg (59 yo)

22yrs

Tenure

€1,783,000

Compensatie

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH.Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joachim Kreuzburg	Chairman of Executive Board & CEO	22yrs	€1.78m	0.040% € 5.5m
Rene Faber	Head of Bioprocess Solutions Division & Member of Executive Board	5.8yrs	€906.00k	geen gegevens
Alexandra Gatzemeyer	Head of the Lab Products & Services Division and Member of Executive Board	1.5yrs	€537.00k	geen gegevens
Petra Kirchhoff	Head of Corporate Communications & Investor Relations and Member of Supervisory Board	7.9yrs	€82.00k	geen gegevens
Florian Funck	CFO & Member of Executive Board	less than a year	geen gegevens	geen gegevens
Patricia Spannagel	Head of Quality Assurance - Mechatronics Division Goettingen	no data	geen gegevens	geen gegevens
Ralf Mohrschladt	Physicist & Head of Supply Chain Management - Germany	no data	geen gegevens	geen gegevens
Petra Muller	Head of Investor Relations	2.8yrs	geen gegevens	geen gegevens
Maurice Phelan	President of Sartorius North America	1.8yrs	geen gegevens	geen gegevens
Theo Thijssen	President of Environmental Technology Division	23.1yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SRT3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Petra Kirchhoff	Head of Corporate Communications & Investor Relations and Member of Supervisory Board	14.1yrs	€82.00k	geen gegevens
Klaus Trutzschler	Independent Member of Supervisory Board	13yrs	€186.00k	geen gegevens
Annette Becker	Employee Representative Member of Supervisory Board	22.2yrs	€120.00k	geen gegevens
Frank Riemensperger	Member of Supervisory Board	2.7yrs	€81.00k	geen gegevens
Lothar Kappich	Chairman of Supervisory Board	17.6yrs	€365.00k	geen gegevens
Daniela Favoccia	Independent Member of Supervisory Board	7.6yrs	€82.00k	geen gegevens
Manfred Zaffke	Employee Representative Vice Chairman of Supervisory Board	10.7yrs	€201.00k	geen gegevens
Ilke Panzer	Independent Member of Supervisory Board	7.6yrs	€82.00k	geen gegevens
David Ebsworth	Independent Member of Supervisory Board	4.8yrs	€82.00k	geen gegevens
Dietmar Muller	Employee Representative Member of Supervisory Board	4.5yrs	€118.00k	geen gegevens
Hermann Ritzau	Member of Supervisory Board	3.7yrs	€82.00k	geen gegevens
Sabrina Wirth	Member of the Supervisory Board	2.7yrs	€81.00k	geen gegevens

7.6yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SRT3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.6 jaar).

Sartorius Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024

Sartorius Announces Executive Board Changes

Sartorius Announces Management Changes for Sartorius North America

Sartorius Aktiengesellschaft, Annual General Meeting, Mar 29, 2023

Recent updates

Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025

Now 21% undervalued

Consensus EPS estimates fall by 14%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 37%

Price target decreased by 7.0% to €287

Second quarter 2024 earnings: Revenues exceed analyst expectations

Now 23% undervalued after recent price drop

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: Revenues miss analyst expectations

Upcoming dividend of €0.74 per share

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Dividend of €0.74 announced

Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024

Sartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024

Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 29%

Price target decreased by 8.9% to €330

Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024

Third quarter 2023 earnings: Revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 21%

Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023

Sartorius Announces Executive Board Changes

Second quarter 2023 earnings: Revenues miss analyst expectations

Investor sentiment improves as stock rises 17%

Price target decreased by 11% to €356

New minor risk - Share price stability

Price target decreased by 9.4% to €386

Consensus EPS estimates fall by 13%

First quarter 2023 earnings released

Upcoming dividend of €1.44 per share at 0.4% yield

Full year 2022 earnings released

Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023

Sartorius Announces Management Changes for Sartorius North America

Investor sentiment improved over the past week

Price target decreased to €436

Sartorius Aktiengesellschaft, Annual General Meeting, Mar 29, 2023

Sartorius Aktiengesellschaft to Report First Half, 2023 Results on Jul 21, 2023

Investor sentiment improved over the past week

Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022

Sartorius AG Proposes Ordinary Dividend for the Year 2021

Sartorius Aktiengesellschaft Provides Consolidated Sales Revenue Guidance for the Fiscal Year 2022 and Reaffirms Consolidated Sales Revenue for the Year 2025

Sartorius Aktiengesellschaft (XTRA:SRT) entered into an agreement to acquire a 62.5% stake in ALS Automated Lab Solutions GmbH.

Sartorius Provides Earnings Guidance for the First Half Ended June 30, 2021

Sartorius Raises Group Earnings Guidance for the Full Year 2021

Sartorius Plans to Acquire Remaining Shares of Cellgenix

Sartorius AG Raises Revenue Guidance for the Year 2021

Sartorius Revises Earnings Guidance for the Year 2021

Sartorius Aktiengesellschaft to Report Fiscal Year 2020 Final Results on Feb 18, 2021

Sartorius Aktiengesellschaft to Report Q1, 2021 Results on Apr 21, 2021

Sartorius Aktiengesellschaft (XTRA:SRT) agreed to acquire just over 50% stake in Biological Industries Israel Beit Haemek Ltd. from Kibbutz Beit Haemek and Fortissimo Capital, L.P. managed by Fortissimo Capital for approximately €45 million.

Sartorius Aktiengesellschaft to Report Q3, 2020 Results on Oct 20, 2020

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd